Glaxosmithkline Biologicals Sa

Glycovaxyn Ag

Janssen Pharmaceuticals, Inc.

Veronica Gambillara

Michael T Kowarik

Michael L Wetter

Stefan Jochen Kemmler

Manuela Mally

Darren Robert Abbanat

Micha Andres Häuptle

Patricia Ibarra Yon

Jan Theunis Poolman

Peter Wilhelmus Maria Hermans

Bert Jacquemyn

Micha A Häuptle

Michael Thomas Kowarik

Micha A Hauptle

Michael Lukas Wetter

Micha Andres Hauptle

Provided herein is anO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Polysaccharide and uses thereof

Provided herein is a novelO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Provided herein is a novelO polysaccharide, O25B. Also provided herein are prokaryotic host cells comprising enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates comprise O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, comprising O25B and/or bioconjugates comprising O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further comprise one or more additional bioconjugates.

Growing community of inventors

Meilen, Switzerland

Veronica Gambillara